首页> 外文期刊>Journal of viral hepatitis. >Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: Possible association with disease progression
【24h】

Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: Possible association with disease progression

机译:幽门螺杆菌在HCV相关慢性肝炎和肝硬化合并或不合并肝细胞癌中的作用:可能与疾病进展相关

获取原文
获取原文并翻译 | 示例
           

摘要

The discovery of Helicobacter hepaticus as a causal agent of hepatitis and hepatocellular carcinoma (HCC) in mice has stimulated interest in looking for Helicobacter species in human liver samples. In this study, we searched for association between H. pylori and HCV-related liver disease. Liver specimens were collected from eighty-five patients; they were divided into five different groups according to liver pathology (METAVIR system). Group I (the 1st control group) consisted of 16 patients with chronic hepatitis C without histological activity. Group II consisted of 25 patients with chronic active hepatitis C, Group III, 17 patients with HCV-related cirrhosis and Group IV, 16 patients with HCV-related cirrhosis and HCC. Group V (2nd control group) consisted of 11 patients suffering from gastro duodenal and gall bladder diseases but negative for HCV. All cases were tested by polymerase chain reaction on liver samples for the presence of H. pylori DNA Cag A gene. Routine biochemical, radiological and RT-PCR for HCV RNA were also performed for all cases. The positivity of H. pylori PCR CagA gene in liver tissue was directly proportional to the severity of liver pathology, this being 75%, 52.9% and 32% in groups IV, III and II, respectively, which was more significant than the 1st and 2nd control groups (P < 0.001). There was a significant difference between H. pylori PCR values when compared to METAVIR staging (F) in different groups (P = 0.001). Helicobacter pylori PCR (Cag A gene) was positive in about 28.2% cases of late fibrosis (F3 + F4) while positivity was (5.9%) in early fibrosis (F1 + F2) (P = 0.0001). There was significant difference between H. pylori PCR (Cag A gene) in liver tissue and METAVIR activity in different groups (P = 0.002) as most of H. pylori PCR-positive cases were METAVIR activity A1 and A2 (15.3% and 12.9%, respectively). There was no association between H. pylori PCR and quantitative HCV RNA (P = 0.531). Also there was no significant difference of Child-Pugh staging in the H. pylori PCR-positive group when compared to the negative group (P = 0.996). There may be an association between the presence of H. pylori (Cag A gene) in the liver and disease progression in HCV-related chronic hepatitis and cirrhosis with and without HCC.
机译:在小鼠中发现肝杆菌是肝炎和肝细胞癌(HCC)的致病因子,激发了人们对在人肝样本中寻找幽门螺杆菌的兴趣。在这项研究中,我们寻找幽门螺杆菌与HCV相关的肝病之间的关联。肝脏标本收集自八十五名患者。根据肝脏病理(METAVIR系统)将其分为五个不同的组。第一组(第一个对照组)由16例无组织学活动的慢性丙型肝炎患者组成。第二组包括25例慢性活动性丙型肝炎患者,第三组,17例HCV相关性肝硬化和第四组,16例HCV相关性肝硬化和HCC。第五组(第二对照组)由11名患有十二指肠和胆囊疾病但HCV阴性的患者组成。通过聚合酶链反应在肝样品上检测所有病例是否存在幽门螺杆菌DNA Cag A基因。 HCV RNA的常规生化,放射学和RT-PCR也适用于所有病例。幽门螺杆菌PCR CagA基因在肝脏组织中的阳性率与肝脏病理的严重程度成正比,在IV,III和II组中分别为75%,52.9%和32%,这比第一和第二组更显着。第二对照组(P <0.001)。与不同组中的METAVIR分期(F)相比,幽门螺杆菌PCR值之间存在显着差异(P = 0.001)。约28.2%的晚期纤维化(F3 + F4)病例中幽门螺杆菌PCR(Cag A基因)阳性,而早期纤维化(F1 + F2)阳性(5.9%)(P = 0.0001)。肝组织中的幽门螺杆菌PCR(Cag A基因)与不同组别的METAVIR活性之间存在显着差异(P = 0.002),因为大多数幽门螺杆菌阳性的病例均为METAVIR活性A1和A2(分别为15.3%和12.9%) , 分别)。幽门螺杆菌PCR和定量HCV RNA之间没有关联(P = 0.531)。与阴性组相比,幽门螺杆菌PCR阳性组的Child-Pugh分期也没有显着差异(P = 0.996)。肝中存在幽门螺杆菌(Cag A基因)与HCV相关的慢性肝炎和有无HCC的肝硬化的疾病进展之间可能存在关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号